CTS 2025 Q3 Earnings Beats Revenue Estimates, Net Income Falls 24.3%

Wednesday, Oct 29, 2025 6:33 am ET1min read
CTS--
Aime RobotAime Summary

- CTS reported Q3 2025 earnings with 8.0% revenue growth to $142.97M, exceeding estimates by $6.57M, but net income fell 24.3% to $13.69M.

- The company narrowed FY2025 guidance to $535–$545M revenue and $2.20–$2.25 adjusted EPS, while shares dropped 8.59% pre-market post-results.

- Transportation ($58.55M) and Industrial ($37.10M) segments drove growth, with CEO Kieran O’Sullivan highlighting strategic acquisitions and a $5M naval defense contract.

- CTS faces margin compression risks in Q4 and ongoing supply chain challenges, but returned $44M to shareholders via dividends and buybacks.

CTS (CTS) reported fiscal 2025 Q3 earnings on October 28, 2025, with revenue rising 8.0% year-over-year to $142.97 million, surpassing expectations by $6.57 million. The company narrowed its full-year guidance to $535–$545 million in revenue and $2.20–$2.25 in adjusted diluted EPS. Despite strong revenue growth, net income declined 24.3% to $13.69 million, and the stock fell 8.59% pre-market following results.

Revenue

Transportation led with $58.55 million in revenue, followed by Industrial at $37.10 million. The Medical segment contributed $21.96 million, while Aerospace & Defense added $25.36 million. Total revenue reached $142.97 million, reflecting an 8.0% year-over-year increase driven by diversified market growth and the SyQwest acquisition.


Earnings/Net Income

Earnings per share (EPS) declined 21.7% to $0.47, down from $0.60 in 2024 Q3. Net income fell to $13.69 million, a 24.3% decrease from $18.08 million in the prior year. The EPS decline indicates a weak earnings performance despite revenue growth.


Post-Earnings Price Action Review

The strategy of buying CTSCTS-- stock on revenue beats and holding for 30 days faces data limitations. While Q3 2025 revenue beat estimates by 4.8%, historical price data for prior revenue beats (2020–2024) is unavailable. The stock dropped 8.59% pre-market after Q3 2025 results, underscoring volatility. With insufficient data to assess long-term effectiveness, the strategy shows limited upside potential. <visualization dataurl="https://cdn.ainvest.com/news/visual/visual_components/viz_yo1uruj4.json"></visualization>


CEO Commentary

Kieran O’Sullivan, CEO, highlighted strong diversified market growth, with 59% of Q3 revenue from industrial, aerospace, and medical segments. He emphasized strategic acquisitions and new contracts, such as a $5 million naval defense project for SyQwest.


Guidance

For FY2025, CTS narrowed sales guidance to $535–$545 million and adjusted diluted EPS to $2.20–$2.25. The company expects margin compression in Q4 but remains optimistic about long-term growth in diversified markets.


Additional News

Recent updates include a narrowed FY2025 outlook, a $5 million naval defense contract win for SyQwest, and $44 million returned to shareholders via dividends and buybacks. The company also reported $110 million in cash reserves and $91 million in long-term debt. Supply chain risks, including rare earth and semiconductor constraints, remain under monitoring.


<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-aime_generated_1761733929998.jpg.png" style="max-width:100%;">

Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet